Please scan this QR code to view the RHP

RED HERRING PROSPECTUS

Dated October 22, 2022

Please read Section 32 of the Companies Act, 2013

100% Book Built Offer

GLOBAL HEALTH LIMITED

CORPORATE IDENTITY NUMBER: U85110DL2004PLC128319

REGISTERED AND CORPORATE OFFICE

CONTACT PERSON

E-MAIL AND TELEPHONE

WEBSITE

Registered Office: Medanta - Mediclinic, E-18,

Rahul Ranjan

E-mail:

https://www.medanta.org

Defence Colony, New Delhi, Delhi 110 024, India

compliance@medanta.org

Corporate Office: Medanta - The Medicity, Sector -

Company Secretary and

38, Gurgaon, Haryana 122 001, India

Compliance Officer

Telephone: +91 124 483 4060

OUR PROMOTER: DR. NARESH TREHAN

DETAILS OF THE OFFER TO THE PUBLIC

Type

Fresh Issue Size

Offer for Sale Size

Total

Eligibility and Share Reservation among QIBs, NIBs, RIBs

Offer size

Fresh

Up to [•] Equity

Up to 50,761,000

Up to [•]

The Offer is being made in terms of Regulation 6(1) of the Securities and

Issue and

Shares aggregating

Equity Shares

Equity

Exchange Board of India (Issue of Capital and Disclosure Requirements)

Offer for

up to ₹5,000

aggregating up to ₹

Shares

Regulations, 2018, as amended ("SEBI ICDR Regulations"). For details of

Sale

million

[•] million

aggregating

share reservation among QIBs, NIBs, RIBs, see "Offer Structure" on page

up to

459.

₹[•] million

DETAILS OF THE OFFER FOR SALE BY THE SELLING SHAREHOLDERS AND THEIR RESPECTIVE WEIGHTED

AVERAGE COST OF ACQUISITION PER EQUITY SHARE

NAME OF THE SELLING

TYPE

NUMBER OF SHARES OFFERED

WEIGHTED AVERAGE

SHAREHOLDER

COST OF ACQUISITION

PER EQUITY SHARE (IN

₹)^

Anant Investments

Investor Selling

Up to 50,661,000 Equity Shares aggregating up to ₹[•]

144.18

Shareholder

million

Sunil Sachdeva (jointly held

Individual Selling

Up to 100,000 Equity Shares aggregating up to ₹[•]

2.02

with Suman Sachdeva)

Shareholders

million

^ Calculated on a fully diluted basis as on date of this Red Herring Prospectus.

RISK IN RELATION TO THE FIRST OFFER

This being the first public issue of Equity Shares of our Company, there has been no formal market for the Equity Shares. The face value of the Equity Shares is ₹2 each. The Floor Price, the Cap Price and Offer Price as determined by our Company and the Investor Selling Shareholder, in consultation with the BRLMs, in accordance with the SEBI ICDR Regulations, and as stated in "Basis for Offer Price" on page 160, should not be considered to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active or sustained trading in the Equity Shares nor regarding the price at which the Equity Shares will be traded after listing.

GENERAL RISK

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does the SEBI guarantee the accuracy or adequacy of the contents of this Red Herring Prospectus. Specific attention of the investors is invited

to "Risk Factors" on page 41.

ISSUER'S AND SELLING SHAREHOLDERS' ABSOLUTE RESPONSIBILITY

Our Company, having made all reasonable inquiries, accepts responsibility for and confirms that this Red Herring Prospectus contains all information with regard to our Company and the Offer, which is material in the context of the Offer, that the information contained in this Red Herring Prospectus is true and correct in all material aspects and is not misleading in any material respect, that the opinions and intentions expressed herein are honestly held and that there are no other facts, the omission of which make this Red Herring Prospectus, as a whole or any of such information or the expression of any such opinions or intentions, misleading in any material respect. Each Selling Shareholder, severally and not jointly, accepts responsibility for and confirms only such statements made by it in this Red Herring Prospectus to the extent such statements specifically pertain to it and its respective portion of the Offered Shares and assumes responsibility that such statements are true and correct in all material respects and are not misleading in any material respect. However, each Selling Shareholder, severally and not jointly, does not assume any responsibility for any other statements, including without limitation, any and all of the statements made by or in relation to our Company or the other Selling Shareholders in this Red Herring Prospectus.

LISTING

The Equity Shares offered through this Red Herring Prospectus are proposed to be listed on the Stock Exchanges (as defined herein) being NSE and BSE. Our Company has received in-principle approvals from each of the BSE and the NSE for the listing of the Equity Shares pursuant to their letters dated October 21, 2021 and October 22, 2021, respectively. For the purposes of the Offer, NSE is the Designated Stock Exchange.

BOOK RUNNING LEAD MANAGERS

Logo and name of the Book Running Lead Manager

Contact Person

Telephone and E-mail

Kotak Mahindra Capital

Ganesh Rane

Tel: +91 22 4336 0000

Company Limited

E-mail: globalhealth.ipo@kotak.com

Credit Suisse Securities (India)

Abhishek Joshi

Tel: +91 22 6777 3885

Private Limited

E-mail: list.medantaipo2021@credit-

suisse.com

Jefferies India Private Limited

Ashutosh Prajapati

Tel: +91 22 4356 6000

E-mail: medanta.ipo@jefferies.com

JM Financial Limited

Prachee Dhuri

Tel: +91 22 6630 3030

E-mail: ghl.ipo@jmfl.com

REGISTRAR TO THE OFFER

KFin Technologies Limited

Contact Person: M Murali Krishna

Tel: +91 40 6716 2222

(formerly known as KFin

Email: globalhealth.ipo@kfintech.com

Technologies Private Limited)

BID/OFFER PERIOD

ANCHOR INVESTOR

Wednesday,

BID/OFFER

Thursday,

BID/OFFER

Monday,

BID/OFFER PERIOD(1)

November 2, 2022

OPENS ON

November 3, 2022

CLOSES ON(2)

November 7, 2022

(1)Our Company and the Investor Selling Shareholder, in consultation with the BRLMs, may consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bid/Offer Period will be one Working Day prior to the Bid/Offer Opening Date.

(2)The UPI mandate end time and date shall be at 5:00 p.m. on Monday, November 7, 2022.

GLOBAL HEALTH LIMITED

Our Company was incorporated as 'Global Health Private Limited' on August 13, 2004 at New Delhi, India as a private limited company under the Companies Act, 1956 pursuant to a certificate of incorporation by the Registrar of Companies, Delhi and Haryana at Delhi ("RoC"). Our Company was then converted into a public limited company under the Companies Act, 2013, pursuant to a special resolution passed by our Shareholders at the EGM held on July 31, 2021 and consequently, the name of our Company was changed to 'Global Health Limited' and a fresh certificate of incorporation dated August 11, 2021 was issued by the RoC. For further details in relation to changes in the name and the registered office of our Company, see "History and Certain Corporate Matters" on page 257.

Registered Office: Medanta - Mediclinic, E-18, Defence Colony, New Delhi, Delhi 110 024, India

Corporate Office: Medanta - The Medicity, Sector - 38, Gurgaon, Haryana 122 001, India

Contact Person: Rahul Ranjan, Company Secretary and Compliance Officer

Tel: +91 124 483 4060; E-mail: compliance@medanta.org; Website: https://www.medanta.org

Corporate Identity Number: U85110DL2004PLC128319

OUR PROMOTER: DR. NARESH TREHAN

INITIAL PUBLIC OFFERING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH ("EQUITY SHARES") OF GLOBAL HEALTH LIMITED (OUR "COMPANY" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹[●] PER EQUITY SHARE (INCLUDING A PREMIUM OF ₹[●] PER EQUITY SHARE) (THE "OFFER PRICE") AGGREGATING UP TO ₹[●] MILLION (THE "OFFER") COMPRISING A FRESH ISSUE OF UP TO [●] EQUITY SHARES BY OUR COMPANY AGGREGATING UP TO ₹5,000 MILLION (THE "FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 50,761,000 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION (THE "OFFER FOR SALE") COMPRISING UP TO 50,661,000 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY ANANT INVESTMENTS (THE "INVESTOR SELLING SHAREHOLDER") AND UP TO 100,000 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY SUNIL SACHDEVA (JOINTLY HELD WITH SUMAN SACHDEVA) (THE "INDIVIDUAL SELLING SHAREHOLDERS", AND ALONG WITH INVESTOR SELLING SHAREHOLDER, THE "SELLING SHAREHOLDERS" AND SUCH EQUITY SHARES OFFERED BY THE SELLING SHAREHOLDERS, THE "OFFERED SHARES"). THE OFFER SHALL CONSTITUTE [●]% OF THE FULLY DILUTED POST-OFFER PAID- UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE FACE VALUE OF THE EQUITY SHARE IS ₹2 EACH AND THE OFFER PRICE IS [●] TIMES THE FACE VALUE OF EQUITY SHARES. THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY AND THE INVESTOR SELLING SHAREHOLDER IN CONSULTATION WITH THE BRLMS AND WILL BE ADVERTISED IN ALL EDITIONS OF THE ENGLISH NATIONAL DAILY NEWSPAPER, FINANCIAL EXPRESS AND ALL EDITIONS OF THE HINDI NATIONAL DAILY NEWSPAPER, JANSATTA (HINDI BEING THE REGIONAL LANGUAGE OF DELHI, WHERE OUR REGISTERED OFFICE IS LOCATED), EACH WITH WIDE CIRCULATION, AT LEAST TWO WORKING DAYS PRIOR TO THE BID/OFFER OPENING DATE AND SUCH ADVERTISEMENT SHALL BE MADE AVAILABLE TO THE BSE LIMITED (THE "BSE") AND THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED (THE "NSE", AND TOGETHER WITH THE BSE, THE "STOCK EXCHANGES") FOR THE PURPOSE OF UPLOADING ON THEIR RESPECTIVE WEBSITES IN ACCORDANCE WITH THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (THE "SEBI ICDR REGULATIONS").

In case of any revision in the Price Band, the Bid/Offer Period will be extended by at least three additional Working Days after such revision of the Price Band, subject to the Bid/Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company and the Investor Selling Shareholder may, in consultation with the BRLMs, for reasons to be recorded in writing, extend the Bid/Offer Period for a minimum of three Working Days, subject to the Bid/ Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/Offer Period, if applicable, will be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the BRLMs and at the terminals of the Syndicate Members and by intimation to the other Designated Intermediaries and the Sponsor Banks, as applicable.

The Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the SCRR read with Regulation 31 of the SEBI ICDR Regulations and in compliance with Regulation 6(1) of the SEBI ICDR Regulations, wherein not more than 50% of the Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs", and such portion, the "QIB Portion"), provided that our Company and the Investor Selling Shareholder may, in consultation with the BRLMs, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis, in accordance with the SEBI ICDR Regulations (the "Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price, in accordance with the SEBI ICDR Regulations. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs (other than Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from the Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Offer shall be available for allocation to Non-Institutional Bidders ("Non-InstitutionalPortion") of which (a) one-third shall be available for allocation to Bidders with an application size of more than ₹200,000 and up to ₹1,000,000 and (b) two-thirds shall be available for allocation to Bidders with an application size of more than ₹1,000,000 provided that under-subscription in either of these two sub-categories of Non-Institutional Portion may be allocated to Bidders in the other sub-category of Non-Institutional Portion in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price, and not less than 35% of the Offer shall be available for allocation to Retail Individual Bidders ("Retail Portion") in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. All potential Bidders, other than Anchor Investors, are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA accounts and UPI ID (defined hereinafter) (in case of UPI Bidders using UPI Mechanism (defined hereinafter)), if applicable, in which the corresponding Bid Amounts will be blocked by the self-certified syndicate banks ("SCSBs") or the Sponsor Banks under the UPI Mechanism, as applicable, to participate in the Offer. Anchor Investors are not permitted to participate in the Anchor Investor Portion through the ASBA process. See "Offer Procedure", on page 463.

RISK IN RELATION TO THE FIRST OFFER

This being the first public issue of Equity Shares of our Company, there has been no formal market for the Equity Shares. The face value of the Equity Shares is ₹2 each. The Floor Price, Cap Price and Offer Price, as determined by our Company and the Investor Selling Shareholder in consultation with the BRLMs, in accordance with the SEBI ICDR Regulations, and as stated in "Basis for Offer Price" on page 160, should not be taken to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active or sustained trading in the Equity Shares nor regarding the price at which the Equity Shares will be traded after listing.

GENERAL RISK

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have not been recommended or approved by the Securities and Exchange Board of India (the "SEBI"), nor does the SEBI guarantee the accuracy or adequacy of the contents of this Red Herring Prospectus. Specific attention of the investors is invited to "Risk Factors" on page 41.

ISSUER'S AND SELLING SHAREHOLDERS' ABSOLUTE RESPONSIBILITY

Our Company, having made all reasonable inquiries, accepts responsibility for and confirms that this Red Herring Prospectus contains all information with regard to our Company and the Offer, which is material in the context of the Offer, that the information contained in this Red Herring Prospectus is true and correct in all material aspects and is not misleading in any material respect, that the opinions and intentions expressed herein are honestly held and that there are no other facts, the omission of which makes this Red Herring Prospectus as a whole or any of such information or the expression of any such opinions or intentions misleading in any material respect. Each Selling Shareholder, severally and not jointly, accepts responsibility for and confirms only such statements made or undertaken expressly by it in this Red Herring Prospectus to the extent such statements specifically pertain to it and its respective portion of the Offered Shares in the Offer for Sale and assumes responsibility that such statements are true and correct in all material respects and not misleading in any material respect. However, each Selling Shareholder, severally and not jointly, does not assume any responsibility for any other statements, including without limitation, any and all of the statements made by or in relation to our Company or the other Selling Shareholders in this Red Herring Prospectus.

LISTING

The Equity Shares offered through this Red Herring Prospectus are proposed to be listed on the Stock Exchanges being the BSE and the NSE. Our Company has received an 'in-principle' approval from each of the BSE and the NSE for the listing of the Equity Shares pursuant to their letters dated October 21, 2021 and October 22, 2021, respectively. For the purposes of the Offer, the Designated Stock Exchange shall be NSE. A signed copy of this Red Herring Prospectus and the Prospectus shall be delivered to the RoC in accordance with Sections 26(4) and 32 of the Companies Act. For details of the material contracts and documents that will be available for inspection from the date of this Red Herring Prospectus up to the Bid/Offer Closing Date, see "Material Contracts and Documents for Inspection" on page 497.

BOOK RUNNING LEAD MANAGERS

REGISTRAR TO THE

OFFER

Kotak Mahindra Capital Company Limited

Credit Suisse Securities (India) Private

Jefferies India Private Limited

JM Financial Limited

KFin Technologies Limited (formerly

1st Floor, 27BKC, Plot No. C - 27

Limited

42/43, 2 North Avenue Maker

7th Floor Cnergy

known as KFin Technologies Private

G Block, Bandra Kurla Complex

9th Floor, Ceejay House

Maxity

Appasaheb Marathe Marg

Limited)

Bandra (East)

Plot F, Shivsagar Estate

Bandra-Kurla Complex

Prabhadevi

Selenium, Tower-B

Mumbai 400 051

Dr. Annie Besant Road, Worli

Bandra (East), Mumbai 400 051

Mumbai 400 025

Plot 31 and 32, Financial District

Maharashtra, India

Mumbai 400 018

Maharashtra, India

Maharashtra, India

Nanakramguda, Serilingampally

Tel: +91 22 4336 0000

Maharashtra, India

Tel: +91 22 4356 6000

Tel: +91 22 6630 3030

Hyderabad, Rangareddi 500 032

E-mail: globalhealth.ipo@kotak.com

Tel: +91 22 6777 3885

E-mail: medanta.ipo@jefferies.com

E-mail: ghl.ipo@jmfl.com

Telangana, India

Investor grievance e-mail:

E-mail:list.medantaipo2021@credit-suisse.com

Investor grievance e-mail:

Investor grievance e-mail:

Tel: +91 40 6716 2222

kmccredressal@kotak.com

Investor grievance e-mail:list.igcellmer-

jipl.grievance@jefferies.com

grievance.ibd@jmfl.com

E-mail:

Website: www.investmentbank.kotak.com

bnkg@credit-suisse.com

Website: www.jefferies.com

Website: www.jmfl.com

globalhealth.ipo@kfintech.com

Contact Person: Ganesh Rane

Website: https://www.credit-

Contact Person: Ashutosh Prajapati

Contact Person: Prachee Dhuri

Investor grievance e-mail:

SEBI Registration No: INM000008704

suisse.com/in/en/investment-banking-

SEBI Registration No.: INM000011443

SEBI Registration Number: INM000010361

einward.ris@kfintech.com

apac/investment-banking-in-india/ipo.html

Website: www.kfintech.com

Contact Person: Abhishek Joshi

Contact Person: M Murali Krishna

SEBI Registration No.: INM000011161

SEBI

Registration

No.:

INR000000221

BID/OFFER PROGRAMME

BID/OFFER OPENS ON: Thursday, November 3, 2022(1)

BID/OFFER CLOSES ON: Monday, November 7, 2022(2)

  1. Our Company and the Investor Selling Shareholder, in consultation with the BRLMs, may consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bid/Offer Period will be one Working Day prior to the Bid/Offer Opening Date.
  2. The UPI Mandate end time and date shall be at 5:00 p.m. on Monday, November 7, 2022.

(This page is intentionally left blank)

TABLE OF CONTENTS

SECTION I: GENERAL ......................................................................................................................

6

DEFINITIONS AND ABBREVIATIONS ........................................................................................................

6

OFFER DOCUMENT SUMMARY ................................................................................................................

20

CERTAIN CONVENTIONS, PRESENTATION OF FINANCIAL, INDUSTRY AND MARKET DATA

AND CURRENCY OF PRESENTATION ......................................................................................................

35

FORWARD-LOOKING STATEMENTS .......................................................................................................

39

SECTION II: RISK FACTORS ........................................................................................................

41

SECTION III: INTRODUCTION.....................................................................................................

92

THE OFFER ....................................................................................................................................................

92

SUMMARY OF FINANCIAL INFORMATION OF THE COMPANY .........................................................

96

SUMMARY OF FINANCIAL INFORMATION OF MHPL AND GHPPL..................................................

105

GENERAL INFORMATION ........................................................................................................................

115

CAPITAL STRUCTURE ..............................................................................................................................

125

OBJECTS OF THE OFFER ...........................................................................................................................

150

BASIS FOR OFFER PRICE ..........................................................................................................................

160

STATEMENT OF SPECIAL TAX BENEFITS ............................................................................................

164

SECTION IV: ABOUT OUR COMPANY .....................................................................................

170

INDUSTRY OVERVIEW .............................................................................................................................

170

OUR BUSINESS ...........................................................................................................................................

224

KEY REGULATIONS AND POLICIES.......................................................................................................

248

HISTORY AND CERTAIN CORPORATE MATTERS ...............................................................................

257

OUR MANAGEMENT .................................................................................................................................

272

OUR PROMOTER AND PROMOTER GROUP ..........................................................................................

296

OUR GROUP COMPANIES.........................................................................................................................

299

DIVIDEND POLICY.....................................................................................................................................

305

SECTION V: FINANCIAL INFORMATION ...............................................................................

306

FINANCIAL STATEMENTS .......................................................................................................................

306

OTHER FINANCIAL INFORMATION .......................................................................................................

373

CAPITALIZATION STATEMENT ..............................................................................................................

375

FINANCIAL INDEBTEDNESS ...................................................................................................................

376

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF

OPERATIONS ..............................................................................................................................................

379

SECTION VI: LEGAL AND OTHER INFORMATION .............................................................

415

OUTSTANDING LITIGATION AND MATERIAL DEVELOPMENTS ....................................................

415

GOVERNMENT AND OTHER APPROVALS ............................................................................................

429

OTHER REGULATORY AND STATUTORY DISCLOSURES .................................................................

436

SECTION VII: OFFER RELATED INFORMATION.................................................................

453

TERMS OF THE OFFER ..............................................................................................................................

453

OFFER STRUCTURE ...................................................................................................................................

459

OFFER PROCEDURE ..................................................................................................................................

463

RESTRICTIONS ON FOREIGN OWNERSHIP OF INDIAN SECURITIES...............................................

483

SECTION VIII: DESCRIPTION OF EQUITY SHARES AND TERMS OF THE ARTICLES OF

ASSOCIATION.................................................................................................................................

485

SECTION IX: OTHER INFORMATION......................................................................................

497

MATERIAL CONTRACTS AND DOCUMENTS FOR INSPECTION .......................................................

497

DECLARATION ...........................................................................................................................................

501

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Global Health Limited published this content on 27 October 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 October 2022 04:33:06 UTC.